ImmunoEngineering Group, School of Cancer and Pharmaceutical Sciences, King's Health Partners Integrated Cancer Centre, Guy's Hospital, King's College London, London, United Kingdom.
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
J Nucl Med. 2019 Jun;60(6):730-735. doi: 10.2967/jnumed.118.213348. Epub 2019 Apr 12.
Cancer immunotherapy is now established as a central therapeutic pillar in hematologic oncology. Cell-based therapies, with or without genetic modification ex vivo, have reached the clinic as the standard of care in limited indications and remain the subject of intense preclinical and translational development. Expanding on this, related therapeutic approaches are in development for solid-tumor and nonmalignant indications, broadening the scope of this technology. It has long been recognized that in vivo tracking of infused cellular therapies would provide unique opportunities to optimize their efficacy and aid in the assessment and management of toxicity. Recently, we have witnessed the introduction of novel tracers for passive labeling of cell products and advances in the introduction and use of reporter genes to enable longitudinal imaging. This review highlights the key developments over the last 5 y.
癌症免疫疗法现在已被确立为血液肿瘤学的主要治疗支柱。基于细胞的疗法，无论是否进行体外基因修饰，已在有限的适应症中达到了治疗标准，并仍然是临床前和转化研究的热点。在此基础上，相关的治疗方法正在开发用于实体瘤和非恶性适应症，扩大了这项技术的应用范围。长期以来，人们一直认为对输注的细胞疗法进行体内追踪将提供优化其疗效的独特机会，并有助于评估和管理毒性。最近，我们见证了用于细胞产品被动标记的新型示踪剂的引入，以及引入和使用报告基因以实现纵向成像的进展。本综述重点介绍了过去 5 年来的关键进展。
